Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
ICON2
Study information
Scientific title
Acronym
Study hypothesis
To compare cyclophosphamide, doxorubicin and cisplatin (CAP) with single-agent carboplatin in patients with advanced ovarian cancer.
Ethics approval
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Ovarian cancer
Intervention
1. Cyclophosphamide, doxorubicin and cisplatin (CAP)
2. Single-agent carboplatin
Intervention type
Drug
Phase
Not Applicable
Drug names
Cyclophosphamide, doxorubicin, cisplatin, carboplatin
Primary outcome measures
1. Survival time
2. Progression-free survival
Secondary outcome measures
Not provided at time of registration
Overall trial start date
01/01/1991
Overall trial end date
31/12/1996
Reason abandoned
Eligibility
Participant inclusion criteria
1. Chemotherapy indicated
2. No previous malignancy
3. No prior radiotherapy or chemotherapy
4. No contraindication to chemotherapy
Participant type
Patient
Age group
Not Specified
Gender
Female
Target number of participants
2000 in 9 countries
Participant exclusion criteria
Does not meet inclusion criteria
Recruitment start date
01/01/1991
Recruitment end date
31/12/1996
Locations
Countries of recruitment
United Kingdom
Trial participating centre
MRC Clinical Trials Unit
London
NW1 2DA
United Kingdom
Sponsor information
Organisation
Medical Research Council (MRC) (UK)
Sponsor details
20 Park Crescent
London
W1B 1AL
United Kingdom
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk
Sponsor type
Research council
Website
Funders
Funder type
Research council
Funder name
Medical Research Council (MRC) (UK)
Alternative name(s)
MRC
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2009 results in: http://www.ncbi.nlm.nih.gov/pubmed/9843101
Publication citations
-
Results
ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study., Lancet, 1998, 352, 9140, 1571-1576.